<DOC>
	<DOCNO>NCT01674647</DOCNO>
	<brief_summary>A study patient abnormal heart rhythm ( atrial fibrillation ) need undergo cardioversion ( procedure restore normal heart rhythm ) . The study compare patient assign randomly ( like flip coin ) either Rivaroxaban vitamin K antagonist ( VKA ) . The study measure common medical outcome type patient bleed stroke .</brief_summary>
	<brief_title>Explore Efficacy Safety Once-daily Oral Rivaroxaban Prevention Cardiovascular Events Subjects With Nonvalvular Atrial Fibrillation Scheduled Cardioversion</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Men woman age &gt; = 18 year Hemodynamically stable nonvalvular atrial fibrillation longer 48 hour unknown duration Scheduled cardioversion ( electrical pharmacological ) nonvalvular atrial fibrillation Women childbearing potential men must agree use adequate contraception sexually active Severe , disable stroke ( modify Rankin score 4 5 , inclusive ) within 3 month stroke within 14 day prior randomization Transient ischemic attack within 3 day prior randomization Acute thromboembolic event thrombosis ( venous/arterial ) within last 14 day prior randomization Acute Myocardial infarction ( MI ) within last 14 day prior randomization Cardiacrelated criterion : know presence cardiac thombus myxoma valvular atrial fibrillation Active bleeding high risk bleed contraindicate anticoagulant therapy Concomitant medication : indication anticoagulant therapy atrial fibrillation , chronic aspirin therapy &gt; 100 mg daily dual antiplatelet therapy , strong inhibitor cytochrome P450 ( CYP ) 3A4 Pglycoprotein ( Pgp ) use systemically Concomitant condition : childbearing potential without proper contraceptive measure , pregnancy , breast feeding ; hypersensitivity investigational treatment comparator treatment ; calculate creatinine clearance ( CrCl ) &lt; 30 mL/minute ; hepatic disease associate coagulopathy lead clinically relevant bleeding risk ; severe condition would limit life expectancy le 6 month ; plan invasive procedure potential uncontrolled bleeding ; inability take oral medication ; ongoing drug addiction alcohol abuse Any contraindication list local label comparator treatment experimental treatment Participation study investigational drug medical device within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>rivaroxaban</keyword>
	<keyword>oral anticoagulant</keyword>
	<keyword>nonvalvular atrial fibrillation</keyword>
	<keyword>cardioversion</keyword>
	<keyword>stroke</keyword>
	<keyword>transient ischemic attack</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>cardiovascular event</keyword>
</DOC>